Dashboard/AGARWALEYE

AGARWALEYE

OVERVALUED

Dr. Agarwal's Health Care Limited

Healthcare · NSE

↓ 714.9% vs fair value

52W Low

₹327

+29.9% from low

52W High

₹568

-25.2% from high

News sentiment (0 articles)

0 bull0 neutral0 bear

Valuation Gauge

OVERVALUED-714.9% Margin of Safety

OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹425

Fair Value

₹52

Fair Value Analysis

₹52

Based on balance sheet strength analysis and earnings growth potential for Healthcare sector companies | Sector-expensive: P/E at 93th percentile vs sector peers. | CAUTION: ROCE declining (latest 16.4%) — returns on capital are falling; verify this isn't a value trap.

Low confidence

Balance Sheet Value

33% weight

₹52

Growth Valuation

67% weight

₹52

Price vs Market

AGARWALEYE

Nifty 50

Technical Pulse

Plain English — no jargon

RSI 38.9Neutral

52-week range-9.7% from high

L 401H 461.95

20-day avg₹428▼ 2.6%

📍

Price PositionNeutral

Not enough price history to assess trend.

💪

Momentum (RSI)Oversold

RSI is 39 — oversold territory. Selling pressure is high but may be slowing.

📈

Short-term TrendNeutral

Insufficient data for short-term trend.

→Combined Verdict

Trading significantly above fair value. Unless you believe the business has permanently re-rated, the risk-reward is unfavorable here.

Shareholding Pattern

Stock Health Score

B+

Financially Healthy

7.2 / 10

Profitability

5/10

EPS of ₹4.0 — ROE data unavailable for full scoring

Debt & Leverage

10/10

D/E ratio of 0.5x is well within the Healthcare sector norm of 0.8x — strong balance sheet

Valuation vs Peers

10/10

P/E of 104.0x trades at a 35% discount to Healthcare sector median (160x) — attractively valued

Cash Flow

4/10

FCF margin of 2.3% — thin cash generation, watch capex trends

Earnings Growth

10/10

5yr EPS CAGR of 30.3% is well above the Healthcare sector average of 18.7% — strong growth

Dividend

4/10

No dividend — typical for growth-stage companies

Sentiment Trend — Last 30 Days

Historical Returns

Key Ratios & Growth

FCF Yield

-2.3%

Free cash flow / market cap

Operating Cash Flow

₹360 Cr

TTM cash from operations

Key Financials

EPS (TTM)

₹4

P/E Ratio

104x

P/B Ratio

8.8x

ROE

—

ROCE

8.4%

Debt / Equity

0.49x

Beta

—

Div Yield

—

FCF (Cr)

₹39 Cr

Revenue (Cr)

₹1,705 Cr

EPS Growth 5Y

30.3%

Mkt Cap (Cr)

₹13,211 Cr

52W High

₹568

52W Low

₹327

Book Value/Share

₹47

Financial History

Period	Revenue	Op Profit	OPM%	PAT	EPS
TTM	₹2.0K Cr	₹539 Cr	27.0%	₹161 Cr	₹3.99
2025-03-31	₹1.7K Cr	₹463 Cr	27.0%	₹110 Cr	₹2.64
2024-03-31	₹1.3K Cr	₹367 Cr	28.0%	₹95 Cr	—
2023-03-31	₹1.0K Cr	₹275 Cr	27.0%	₹103 Cr	—
2022-03-31	₹696 Cr	₹186 Cr	27.0%	₹43 Cr	—
2021-03-31	₹471 Cr	₹85 Cr	18.0%	₹-59 Cr	—
2020-03-31	₹531 Cr	₹124 Cr	23.0%	₹-21 Cr	—

Compounded Growth Rates

Sales Growth

3Y+24.7%

5Y+33.2%

10Y—

Profit Growth

3Y+16.1%

5Y—

10Y—

EPS Growth

3Y—

5Y—

10Y—

Peer Comparison

Healthcare

Stock	Price	Fair Value	MoS%	P/E	ROE	Signal
ALPA Alpa Laboratories Limited	₹62.1	₹198.5	+68.7%	9.4	13.4%	FAIRLY_VALUED
ASTERDM Aster DM Healthcare	₹670	₹1,585.8	+57.8%	103.2	7.9%	UNDERVALUED
UNICHEMLAB Unichem Laboratories Limited	₹300	₹592.5	+49.4%	7.1	12.1%	FAIRLY_VALUED
DCAL Dishman Carbogen Amcis Limited	₹147.6	₹281.2	+47.5%	19.5	1.9%	FAIRLY_VALUED
VIMTALABS Vimta Labs Limited	₹414.8	₹722.6	+42.6%	24.6	16.6%	UNDERVALUED
MOREPENLAB Morepen Laboratories Limited	₹38.4	₹52.8	+27.2%	21	10.8%	FAIRLY_VALUED
INDRAMEDCO Indraprastha Medical Corporation Limited	₹410	₹462.6	+11.4%	20	20.6%	FAIRLY_VALUED
KRONOX Kronox Lab Sciences Limited	₹133	₹130.7	-1.8%	16.9	24.8%	FAIRLY_VALUED

Institutional Activity

Bulk deals, block deals, short selling & delivery volume — NSE data

Insider Trading

Community Pulse

What is Dalal Street saying?

r/IndiaInvestments · r/Dalal_Street_Investments · r/IndianStockMarket

No Reddit mentions found yet for AGARWALEYE.

StockTwits

What traders are saying right now

StockTwits

No StockTwits activity found for AGARWALEYE.

Search Interest

Google Trends · India · Last 90 days

Trends

Trend data not yet available — check back soon.

Telegram Channels

ET Markets · CNBC TV18 · Moneycontrol · Zee Business · NDTV Profit

No Telegram mentions found yet for AGARWALEYE.

6 articles

Dr. Agarwal's Health Care Officially Ends Idearx Services Associate Status - scanx.trade

Google News: AGARWALEYE·7d ago

Stock to buy: Avendus initiates coverage on Dr Agarwal’s Health Care with 'buy' rating; sees 18.3% upside - MSN

Google News: AGARWALEYE·12d ago

Stock to buy: Avendus initiates coverage on Dr Agarwal’s Health Care with 'buy' rating; sees 18.3% upside - Mint

Google News: AGARWALEYE·13d ago

Dr. Athiya Agarwal Acquires 14,41,568 Shares of Dr. Agarwal's Health Care Through Inter-se Transfer - scanx.trade

Google News: AGARWALEYE·14d ago

Dr. Athiya Agarwal Promoter Group Inter-Se Share Transfer Announced for Dr. Agarwal's Health Care Limited - InvestyWise

Google News: AGARWALEYE·14d ago

Avendus Spark Initiates 'Buy' On Dr Agarwal's Health Care, Sees Growth Prospects - NDTV Profit

Google News: AGARWALEYE·14d ago

Company Documents

Annual reports, concall transcripts & regulatory filings

📄

Annual Reports

Last 10 years of annual reports via Screener.in

↗🎙️

Concall Transcripts

Quarterly earnings call transcripts & investor presentations

↗🏛️

NSE Filings

Board meeting outcomes, shareholding patterns, corporate actions

↗📊

Balance Sheet & Cash Flow

10-year financial statements on Screener.in

↗

Share this Stock

Download card · Share on WhatsApp

Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant